No abstract

The aim of this study was to assess the effects of nicotinamide adenine dinucleotide hydride (NADH) on maximal oxygen uptake (VO2max), maximal anaerobic running time, and mental performance. Eight men were exposed to a supplement treatment (30 mg NADH as ENACHI tablets per day) and to a placebo treatment, each of 4 weeks' duration, in a balanced, double-blind, and cross-over design. The two treatments were separated by a 14-week wash-out period. The results indicated that VO2max, maximal anaerobic running time, and the ability to concentrate were similar in the NADH and placebo conditions. There were also no differences in blood lactate, creatine kinase, reaction time or feelings of fatigue between the treatments. A counter-movement jump performed at rest and 2 min after the aerobic test differed significantly (P

Twenty patients with diabetes type-2, aged between 38 and 61 years, with at least one cardiovascular risk factor were divided in two groups (Group-1 included newly diagnosed type 2 diabetic patients without treatment with oral antidiabetic OAD, Group-2: patients with diabetes type 2 under OAD +/-insulin (N = 11)). Patients from both groupswere taking Nicotinamide Adenine Dinucleotide (NADH) Rapid Energy® 80 mg/day in two takes for a period of 56 days. A greater reduction in average fasting glucose and HbA1c after 56 days was observed in the patients of group 1 not taking metformin compared to patients of group-2 which were taking metformin. Why metformin reduces the anti-diabetic effect of NADH will be discussed.